{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Austria Medical Devices news", "home_page_url": "https://sharemaestro.com/newsreel/at/healthcare/medical-devices/", "feed_url": "https://sharemaestro.com/newsreel/at/healthcare/medical-devices/feed.json", "description": "Latest Medical Devices company headlines from Austria, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:350e8b0f908a191d1ec65427f675fa0c0434ffe64637da431ccf76d5a5533ef2", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-syk-still-look-undervalued-031601632.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-syk-still-look-undervalued-031601632.html", "title": "Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Str", "date_published": "2026-08-14T03:16:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:352a0f3761594e28dc3c1d362f7b538ee156b891d3026295e72946763c29c5ee", "url": "https://finance.yahoo.com/markets/stocks/articles/syk-worth-buying-growth-improves-174900186.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/syk-worth-buying-growth-improves-174900186.html", "title": "Is SYK Worth Buying as Growth Improves but Execution Risks Persist?", "content_text": "Stryker Corporation SYK presents a growth-versus-execution decision. Second-quarter sales and earnings improved sharply as the company recovered from its first-quarter cybersecurity disruption, while margins expanded and demand remained broad. The case is not risk-free. Cyber remediation costs, vascular supply constraints and acquisition execution still matter. For investors, the question is whether Stryker's improving fundamentals and product pipeline justify adding exposure before those operating issues are fully resolved. SYK's Growth Case Is Stronger Than Its Risk Profile Stryker delivered", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:84980dbc017c4e1caacf816c96701866d11ab80a0313de34674c2e716016b3b7", "url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "title": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?", "content_text": "Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:0cfcde4cddab96709ddbfbea14351e5e47db7dc607b47c80b30ee36a5f942748", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-bulls-look-optimistic-133003681.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-bulls-look-optimistic-133003681.html", "title": "Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?", "content_text": "The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Medtronic (MDT). Medtronic currently has an average brokerage recommendation (ABR) of 1.90, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated", "date_published": "2026-08-13T13:30:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:3b735e4b7d6de1b3802d4be91d33a8ae5f25622babda52dafd79d81fd27b4acd", "url": "https://finance.yahoo.com/technology/articles/priori-expands-client-advisory-board-130000660.html", "external_url": "https://finance.yahoo.com/technology/articles/priori-expands-client-advisory-board-130000660.html", "title": "Priori Expands Client Advisory Board with New Members from Fortune 500 Corporate Legal Departments", "content_text": "Priori Legal operations and legal department leaders from Mastercard, Meta, Google, Uber, General Motors, U.S. Bank, Capital One and more will help shape the future of outside counsel management NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Priori, the legal technology company modernizing outside counsel management and hiring, today announced the members of its 2026\u20132027 Client Advisory Board (CAB), a group of senior legal operations and legal department leaders who provide strategic guidance on the company's product roadmap and the evolving needs of modern in-house legal teams. The 2026\u20132027 CA", "date_published": "2026-08-13T13:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:6bebd5c6d2f8662a74ba8d37058c7efaf4228f2893397c2e5001d65410bc2a61", "url": "https://finance.yahoo.com/markets/stocks/articles/edwards-climbs-14-3-months-125100456.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/edwards-climbs-14-3-months-125100456.html", "title": "Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation", "content_text": "Edwards Lifesciences Corporation EW shares have gained 14% in the past three months as growth across its structural-heart franchises has strengthened the operating case. Second-quarter results showed double-digit expansion in transcatheter aortic valve replacement and faster growth in transcatheter mitral and tricuspid therapies. The rally leaves investors balancing broader growth and raised 2026 expectations against a valuation that already reflects meaningful execution. EW's 3-Month Gain Meets a Premium Valuation EW trades at 28.8X forward 12-month EPS, above 27.3X for the Zacks sub-industry", "date_published": "2026-08-13T12:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "EWLS", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EWLS", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8f4b98af-740c-4156-9751-800d00b35782/"}, {"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:44eba28bf78d020546e41c688eb9802fde66248b39f513d8609af0d73f4e7a33", "url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "external_url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "title": "What's Backing Abbott's Established Pharmaceuticals Division Growth", "content_text": "Abbott Laboratories' ABT Established Pharmaceuticals Division (\"EPD\") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD's diversified geographic footprint and its ability to ", "date_published": "2026-08-13T12:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/cf54f4b1-bfef-442f-8391-620f950a11ca/"}, {"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:377de25772740c4444894cc2e57c9a08c195fe57135370fa67dc64a63d10f303", "url": "https://finance.yahoo.com/markets/stocks/articles/fitlife-brands-inc-ftlf-beats-124002204.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/fitlife-brands-inc-ftlf-beats-124002204.html", "title": "FitLife Brands Inc. (FTLF) Beats Q2 Earnings and Revenue Estimates", "content_text": "FitLife Brands Inc. (FTLF) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this company would post earnings of $0.14 per share when it actually produced earnings of $0.17, delivering a surprise of +21.43%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. FitLife Brands , which belongs t", "date_published": "2026-08-13T12:40:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:e62631285d7721245ec3e28a17d057d0d95d03a031f7951167d433420fe5c569", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "title": "Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle", "content_text": "Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter \"wasn't a huge catch up thus year not yet de-risked,\" leaving \"a higher-than-normal burden on 2H to deliver.\" As a result, Wolfe sees the near-term skew to estimates \"leans negative,\" with growth \"more likely to slow to 8% vs speed up to 10% in 2027.\" The firm flagged that Stryker'", "date_published": "2026-08-13T12:37:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:1e0cde33e45bc82a30375dfc4c94e9b07cb308ddf22aac26c5b00ca8d2be89dd", "url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "external_url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "title": "Revisiting Former Stock Picks Medtronic, Quantas Services, Lennar", "content_text": "Reassessing stock picks is one of the best habits an investor can build. Watch Doug discuss recent stock picks, provide input on the current market environment\u2014and take your questions. The daily chart illustrates how well the stock has performed relative to its peers on the ratio chart against the over the past two months. Continue Reading", "date_published": "2026-08-13T04:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:e2e53014098505128ba9b042fa06f1f76e2cbe50dbb782d539fd1cf552748935", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "title": "DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?", "content_text": "DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace with higher expectations. Recent results support the fundamental case, but the stock's premium valuation leaves less room for disappointment. Investors now have to weigh improving execution against competition and litigation risk. DXCM's 52.5% Rally Outpaces Key Benchmarks DXCM's three-month gain easily exceeds the 18.3% rise for th", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DXCM"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DXCM", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/329a599c-4f56-47bb-a86c-cd2dc8943cb2/"}]}}, {"id": "source:2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "content_text": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "date_published": "2026-08-12T17:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT", "ZBH"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}, {"symbol": "ZBH", "name": "Zimmer Biomet Holdings, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/c1109ce3-5dca-4fde-9e15-4835c6b42d0f/"}]}}, {"id": "source:28464d7f630b6fe0e2fe69a3ed0f344e802908c497a4e59e26d792666082de61", "url": "https://finance.yahoo.com/markets/stocks/articles/pbh-syk-better-value-stock-154004051.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/pbh-syk-better-value-stock-154004051.html", "title": "PBH or SYK: Which Is the Better Value Stock Right Now?", "content_text": "Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade ", "date_published": "2026-08-12T15:40:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:236f34736a111bb242258345d7e1c88edda917f48b269c364f2bb5538f36f2f3", "url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "title": "Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis", "content_text": "\"We Give Blood\" brings together all 18 Big Ten\u00ae schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the country Abbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26 Anyone can donate blood anywhere in the U.S. between", "date_published": "2026-08-12T13:14:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/cf54f4b1-bfef-442f-8391-620f950a11ca/"}]}}, {"id": "source:93a8437a003e42bdc1cec61e325e382b08164d5e79e56bcc2ecbd8cc4c72cb21", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "content_text": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "date_published": "2026-08-12T12:25:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:578a0f2db601796dd5dbafacfdc29748269b258cca81fd8d2fed95ac1f7dea2e", "url": "https://finance.yahoo.com/healthcare/articles/does-medtronic-mdt-still-trade-023547555.html", "external_url": "https://finance.yahoo.com/healthcare/articles/does-medtronic-mdt-still-trade-023547555.html", "title": "Does Medtronic (MDT) Still Trade At A Discount After Its CE Mark Win?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic stock has delivered a 20.8% gain over the past three years, yet current checks suggest it now sits close to its estimated intrinsic value rather than at a clear discount. At the same time, earnings-based multiples still screen the shares as undervalued, which sets up a debate over how much upside is left from here. A 20.8% return over three years points to steady value creation for Medtronic shareholders, not a rapid rerating. Progress in highe", "date_published": "2026-08-12T02:35:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:3bf2015a6ce2ced2f87e26937dcd8479b658b132dcf936333e06145737974302", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Hat die Heraufstufung von Medtronic (MDT) durch die UBS nach dem starken, vom Herzbereich getragenen Wachstum gerade das Anlage-Narrativ des Unternehmens ver\u00e4ndert?", "content_text": "Hat die Heraufstufung von Medtronic (MDT) durch die UBS nach dem starken, vom Herzbereich getragenen Wachstum gerade das Anlage-Narrativ des Unternehmens ver\u00e4ndert?", "date_published": "2026-08-11T23:40:03+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:640f91104b792f847e01800e8eb1613daed98a78b72905c44aa08b953c433f86", "url": "https://finance.yahoo.com/healthcare/articles/stryker-syk-comeback-quarter-looks-212323255.html", "external_url": "https://finance.yahoo.com/healthcare/articles/stryker-syk-comeback-quarter-looks-212323255.html", "title": "Stryker\u2019s (SYK) Comeback Quarter Looks Great, But At What Cost?", "content_text": "Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that had rattled its business, and CEO Kevin Lobo pointed to that recovery as proof of the company's resilience. But a closer look at how those earnings were adjusted tells a more complicated story about what is really driving the bottom line.Stryker's (SYK) Comeback Quarter Looks Great, But At What Cost? Bull Case: Growth That Touched Every Corner Of Th", "date_published": "2026-08-11T21:23:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:7cd8b308fd1ba8ee1d12f8541454ba69d33a2e88a8e29e6993906d377fa06a13", "url": "https://finance.yahoo.com/markets/stocks/articles/top-research-reports-meta-texas-203100631.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/top-research-reports-meta-texas-203100631.html", "title": "Top Research Reports for Meta, Texas Instruments & CrowdStrike", "content_text": "Tuesday, August 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Texas Instruments Inc. (TXN) and CrowdStrike Holdings, Inc. (CRWD), as well as a micro-cap stock Weyco Group, Inc. (WEYS). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team t", "date_published": "2026-08-11T20:31:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:87f3f3c3d7a52b0e838831f823951d5707a7816c1b703a90b5d58c54f9f329f6", "url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-wins-analyst-upgrades-191512624.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-wins-analyst-upgrades-191512624.html", "title": "Medtronic (MDT) Wins Analyst Upgrades, Is It Fully Priced?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic (MDT) has moved back into focus after multiple analyst upgrades tied to what they describe as the company's strongest annual revenue growth in a decade, supported by its cardiac portfolio and new product launches. See our latest analysis for Medtronic. Over the past quarter Medtronic has picked up momentum, with a 90 day share price return of 16.39% and a 30 day gain of 6.61%, while the 1 year total shareholder return is close to flat and the 5", "date_published": "2026-08-11T19:15:12+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:1669df33eaba3e6eee9714c010f314c05d1e8287e8ce389932ee77aaead1dfe1", "url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "title": "The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run", "content_text": "Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue competition. The dV5 supercycle is early, with only 1,700 of nearly 13,000 total systems upgraded and over 100 platform updates still planned. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. ", "date_published": "2026-08-11T13:09:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "SYK", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}, {"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:a7cc9f369a9e2ed3cd16858a5d3b642a5276c8871db9133dde26f3c04ec07faa", "url": "https://finance.yahoo.com/healthcare/articles/versa-vascular-appoints-bill-shields-120000282.html", "external_url": "https://finance.yahoo.com/healthcare/articles/versa-vascular-appoints-bill-shields-120000282.html", "title": "Versa Vascular Appoints Bill Shields as Chief Executive Officer", "content_text": "Company Expands Series C Financing to $42M SANTA CRUZ, Calif., August 11, 2026--(BUSINESS WIRE)--Versa Vascular, Inc., a pioneering medical device company dedicated to transforming tricuspid valve disease treatment, announced the appointment of Bill Shields as Chief Executive Officer. Former Versa CEO David Hovda is retiring and will remain an advisor to the company. Shields spent the last 15 years with Medtronic's structural heart franchise, most recently as Vice President and General Manager of its Transcatheter Mitral and Tricuspid Therapies division, where he spent seven years leading prod", "date_published": "2026-08-11T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "SYK", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}, {"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:1e0e00363db074638cbc860140fc49273515a220d295b2895102a2c88136eada", "url": "https://finance.yahoo.com/healthcare/articles/pulsed-field-ablation-global-market-090500258.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pulsed-field-ablation-global-market-090500258.html", "title": "Pulsed Field Ablation Global Market Report 2026 Now Available - Profiles Boston Scientific, Medtronic, Biosense Webster, and 15 Other Players", "content_text": "Company Logo Pulsed Field Ablation MarketPulsed Field Ablation Market Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Area, Source of Ablation, Key Geographical Regions, and Sales Forecast of Leading Players - Trends and Forecast till 2035\" has been added to ResearchAndMarkets.com's offering. The global pulsed field ablation market is projected to expand from approximately USD 3.2 billion in 2026 to USD 14.6 billion by 2035, representing a compound annual growth rate of 18.4% during the forecast period. Rising atr", "date_published": "2026-08-11T09:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:1c8e1137cbdd39b6aea8b289794d24a367c007eba5a577b44e7c22e467624381", "url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "title": "Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?", "content_text": "Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Medtronic (NYSE:MDT), meanwhile, continued to build on its turnaround, reporting its strongest annual revenue growth in a decade as several high-growth platforms gained momentum. So, which is the more compelling long-term ", "date_published": "2026-08-10T22:46:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:99a501eedeb3958ebe6a4d1351adb2e9a43c8bc2f34e87f9aa19ae7d64103286", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "title": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?", "content_text": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar", "date_published": "2026-08-10T22:36:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:1810cfe780396af526d2dcbea72cac0b1203480f9a77542bd5f76951829891ea", "url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-increases-despite-market-214502376.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-increases-despite-market-214502376.html", "title": "Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know", "content_text": "In the latest close session, Medtronic (MDT) was up +2.58% at $89.41. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq lost 0.32%. The medical device company's stock has climbed by 3.92% in the past month, exceeding the Medical sector's loss of 0.38% and the S&P 500's gain of 3.42%. The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on September 1, 2026. On that day, Medtronic is projected to report earnings of $1.39 per share, which wo", "date_published": "2026-08-10T21:45:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:d010ce60e0526c4316a61eeda2801e4969c0e0ffa92f85fbf34fe5b5ce5e3794", "url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-reports-second-quarter-201200454.html", "external_url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-reports-second-quarter-201200454.html", "title": "Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates", "content_text": "Orchestra BioMed Holdings, Inc. The BACKBEAT global pivotal trial (\"BACKBEAT Trial\"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met. Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand. Company to host R&D Day on November", "date_published": "2026-08-10T20:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:927f9ccad8a76401c0a14360109ddd557d24db34a3e730f18f16ee3d81dbc74b", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "external_url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "content_text": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1", "date_published": "2026-08-10T14:42:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:c2cae5d842d00a04b75cba6303708340781f4106ae510a70c537c7440b2dcae8", "url": "https://finance.yahoo.com/markets/stocks/articles/said-4-dividend-aristocrats-could-134539654.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/said-4-dividend-aristocrats-could-134539654.html", "title": "We Said These 4 Dividend Aristocrats Could Soar. Here\u2019s How They Did, Plus 3 New Picks.", "content_text": "Quick Read ABBV surged 47% and BDX gained 26% over the past year, both decisively beating the market as their overlooked dividend growth drove outsized returns. All four original picks kept raising dividends regardless of price, with PG marking its 70th consecutive year of increases and BF-A its 82nd. ALB, MDT, and SWK offer cyclical, defensive, and industrial dividend plays, each with dramatically improved free cash flow coverage heading into fiscal 2027. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to ", "date_published": "2026-08-10T13:45:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:6a7f281ce2bb1823c3712f316b0761ba9ab889f185b0fe61e52d14c509cd0ab6", "url": "https://finance.yahoo.com/markets/stocks/articles/varex-imaging-vrex-q3-earnings-121505093.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/varex-imaging-vrex-q3-earnings-121505093.html", "title": "VAREX IMAGING (VREX) Q3 Earnings Beat Estimates", "content_text": "VAREX IMAGING (VREX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +40.91%. A quarter ago, it was expected that this company would post earnings of $0.22 per share when it actually produced earnings of $0.21, delivering a surprise of -4.55%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. VAREX IMAGING, which belongs to the ", "date_published": "2026-08-10T12:15:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:455f96e15db4bb8b0af01b95c9642b11502fa4455a603549f01df4629a717c6c", "url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-becoming-turnaround-story-234359487.html", "external_url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-becoming-turnaround-story-234359487.html", "title": "Is Medtronic (MDT) Becoming a Turnaround Story?", "content_text": "UBS upgraded Medtronic (NYSE:MDT) to a Buy from Neutral today, telling investors in a research note that a \"turnaround\" is underway at the company. The upgrade raises an important question for investors: Is Medtronic finally returning to sustainable growth after years of underperformance, or is it too early to call the turnaround complete?Truist Maintains Hold on Medtronic (MDT), Seeks Stronger EPS Growth Bull case One of the most prominent factors supporting Medtronic's (NYSE:MDT) turnaround story is the company's reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and", "date_published": "2026-08-09T23:43:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:74027870843f0593cb643644b9d6f9fd9fb11f95387d065058d48179815d88bd", "url": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "title": "Zimmer Biomet Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased 4.6%. Technology and hip products led performance: Hip sales grew 5.1%, while technology, data, bone cement and surgical sales surged 21.5%, supported by strong ROSA, TMINI and OrthoGrid adoption. Knee sales were nearly flat, with international weakness\u2014especially in China\u2014offsetting U.S. gains. Zimmer Biomet raised", "date_published": "2026-08-09T18:03:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZBH"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZBH", "name": "Zimmer Biomet Holdings, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/c1109ce3-5dca-4fde-9e15-4835c6b42d0f/"}]}}, {"id": "source:cfa2e9eeef0f04003ff3ff3d17190b682d47e0feabacf8398b58a2ff1baa3870", "url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "external_url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "title": "Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?", "content_text": "Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic \u203a Medtronic(NYSE: MDT) and Intuitive Surgical(NASDAQ: ISRG), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there ", "date_published": "2026-08-08T21:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:1ddce439bd9138bf0752cae2bcd69d82195a111d8c89e85c9f0e7ea459cb4b5d", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFA0c1JLYWZzMHhvR2xfbXBOOG80bWtzUm9FNFhpcW1iYnVpZmdvMkRmUEl0MXpDWGJkVE5zbHZySmVVVVUwQjg0aFRLZG4zbWtBRndWeUUxVXhDRUNHWkVGZmNEdUtOMnBt?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFA0c1JLYWZzMHhvR2xfbXBOOG80bWtzUm9FNFhpcW1iYnVpZmdvMkRmUEl0MXpDWGJkVE5zbHZySmVVVVUwQjg0aFRLZG4zbWtBRndWeUUxVXhDRUNHWkVGZmNEdUtOMnBt?oc=5", "title": "Stryker Corp (SYK) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "content_text": "Stryker Corp (SYK) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "date_published": "2026-08-08T16:55:03+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:0228fda7a01299989d2cdb3dc45402850ea86f8309b6e3713d2645b01b96fb53", "url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "external_url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "title": "Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech", "content_text": "Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 stocks we like better than Intuitive Surgical \u203a Intuitive Surgical(NASDAQ: ISRG) can be hard to own because the stock is prone to deep drawdowns. It is in a drawdown right now, with the stock down roughly 40% from its early 2025 high. Even after that drop, the price-to-earnings ratio remains lofty at 42x. Th", "date_published": "2026-08-08T16:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:ef97591fe7287717984e55a5dbfd4afdc7056c911aa271ab0319d5876ea6e60b", "url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "external_url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "title": "The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%", "content_text": "Quick Read ISRG dropped 34% on a slower procedure growth guide, yet Q2 EPS of $2.80 crushed the $2.50 consensus for a fifth straight quarterly beat. ISRG trades 28% below Wall Street consensus while peers MDT and SYK fell less than 10% YTD, suggesting the market overcorrected on the category leader. Bernstein's $685 target implies 83% upside with the bull case hinging on the da Vinci 5 upgrade cycle mirroring the prior seven-year Xi ramp. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. Intui", "date_published": "2026-08-08T11:05:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "SYK", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}, {"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:671572b3e5e6a2110370c18bc4ef262aa0e2a67f003cf83baf9a10688b42ab95", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE0xQ0xMQ28zLWVheF9JTUhneTh0WERvY1pfUDFReENNMDVONnN1U2dqV0VDYXQtY0tKR1BmZUFhQmlkcTRYbDlDa2YxajZBRVBuUUs4b0ZFZVBBZk5hWVdJZWVRTVVxTm5F?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE0xQ0xMQ28zLWVheF9JTUhneTh0WERvY1pfUDFReENNMDVONnN1U2dqV0VDYXQtY0tKR1BmZUFhQmlkcTRYbDlDa2YxajZBRVBuUUs4b0ZFZVBBZk5hWVdJZWVRTVVxTm5F?oc=5", "title": "Medtronic PLC (MDT) Aktienanalyse & Prognose", "content_text": "Medtronic PLC (MDT) Aktienanalyse & Prognose", "date_published": "2026-08-08T10:01:56+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:8a4a791cca70b4beebb809c5f2a1ed4b675fe78145cbd17af5a9f36e22a31096", "url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html", "external_url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html", "title": "Medtronic (MDT) Wins Expanded CE Mark For Affera System In Ventricular Arrhythmias", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Medtronic (NYSE:MDT) receives expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter for ventricular arrhythmia treatment. The Sphere-9 catheter also holds a Breakthrough Device Designation from the U.S. FDA, which highlights its potential clinical impact. This broader regulatory progress could influence Medtronic's position in cardiac arrhythmia care across international markets. As cardiac care technology evolves and Medtronic advances ", "date_published": "2026-08-08T02:09:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:23cd29beb951aeaf64abd21990b77a6486bd143e9e9856ac4e3b72edad46cb0e", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOMnBsOC1TaXNTRmYtdTFHZ1BzMmtSUjFQaXNCZGFsLXczeE9Zcng2NHRoSWpWb3N6RXpibWp1cE1XMnlFZnhhZ1R6ZFJYeHp2WlBGZS1EX184cGwwOU43OE5LYlF2bWlOUWhEY1J5X3Y1R2tPMmg4eWVxVXRRTjNlNlU1RlVaUGFJdW5NS3pXSk9BRjJwd19nR1JHdjAzODYzekNEZTBpdmVTNjAxcDRFajFGeGJyN3RGUFZ0VzhEOUNuV2EzenY1X19KOA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOMnBsOC1TaXNTRmYtdTFHZ1BzMmtSUjFQaXNCZGFsLXczeE9Zcng2NHRoSWpWb3N6RXpibWp1cE1XMnlFZnhhZ1R6ZFJYeHp2WlBGZS1EX184cGwwOU43OE5LYlF2bWlOUWhEY1J5X3Y1R2tPMmg4eWVxVXRRTjNlNlU1RlVaUGFJdW5NS3pXSk9BRjJwd19nR1JHdjAzODYzekNEZTBpdmVTNjAxcDRFajFGeGJyN3RGUFZ0VzhEOUNuV2EzenY1X19KOA?oc=5", "title": "Stryker Aktie: Analysten senken Kursziele nach Guidance-Enge", "content_text": "Stryker Aktie: Analysten senken Kursziele nach Guidance-Enge", "date_published": "2026-08-03T13:50:59+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:cf8878afbe3d924863128e8fac715b5e982d537610ffd3dbdb935f7c904a3c78", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNOGhhZkJ4ZXRCZ3o1WjZodUU4eWxBa3lRNG5FQURWY0FLSlFiUWRVRDhPanBqaEFfZ0lVeTZzWTM4b0RrRE9OaVR6MW9SYzR4Q2Z3cHNBZjBfR1hxMEpRU0dGLVlIQmQ3dTROSWJOVjBTdFNiUnpNZ3FpWWV6ekxKVFlfaGJiNVE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNOGhhZkJ4ZXRCZ3o1WjZodUU4eWxBa3lRNG5FQURWY0FLSlFiUWRVRDhPanBqaEFfZ0lVeTZzWTM4b0RrRE9OaVR6MW9SYzR4Q2Z3cHNBZjBfR1hxMEpRU0dGLVlIQmQ3dTROSWJOVjBTdFNiUnpNZ3FpWWV6ekxKVFlfaGJiNVE?oc=5", "title": "Stryker Aktie: Guidance-Enge sorgt f\u00fcr Absturz", "content_text": "Stryker Aktie: Guidance-Enge sorgt f\u00fcr Absturz", "date_published": "2026-08-03T11:02:08+00:00", "authors": [{"name": "finanztrends.de"}], "tags": ["Market update", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:8f8dfcf6a97176dd948e428186cec2b346bd35e62faa18fe2a7a1e6692792253", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPU2pYeHJ1TWpQUmh6VUJ6Z0Z6ODJTZW1zY1g1R1V2RlVva3ZPU0tqTjZmaUU5a0dzY2VtTmZycVBNd2wtaVdrc3dGdWN4eWZrNHFzc1JEaF9HMFMyNEpDcks4dnFnSnBydUxHVE45Tl9RUlFHcTVJQWtEWF9BTDlwYUdla2JVZlhlR2FhNnZRN3RXSEdVVVNfaFM3WVN2eTdlOFRQLUkwY2NaN21pcHI4?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPU2pYeHJ1TWpQUmh6VUJ6Z0Z6ODJTZW1zY1g1R1V2RlVva3ZPU0tqTjZmaUU5a0dzY2VtTmZycVBNd2wtaVdrc3dGdWN4eWZrNHFzc1JEaF9HMFMyNEpDcks4dnFnSnBydUxHVE45Tl9RUlFHcTVJQWtEWF9BTDlwYUdla2JVZlhlR2FhNnZRN3RXSEdVVVNfaFM3WVN2eTdlOFRQLUkwY2NaN21pcHI4?oc=5", "title": "Stryker Aktie: 6,43-Prozent-Einbruch trotz Prognose-Anhebung", "content_text": "Stryker Aktie: 6,43-Prozent-Einbruch trotz Prognose-Anhebung", "date_published": "2026-08-02T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:1715c9b4f828721a36b0e5c2f14215b38930646e653aa7367dac79f3616d4e60", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBoUGxWOTZQRnpTRzlydC1Nd3hJVW9pdjR5ODJOazJDQXEwT1Q5YUZpTzRnODZQY2lQY2NXR0lrV1NvVlVvTTVNZXlNdUJnanhRSjV2dkJzaTZkLVkxYlo1NGhTYzBlQVR0Y2c5WkdEaldxSW85bm50VU16RVVfNEE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBoUGxWOTZQRnpTRzlydC1Nd3hJVW9pdjR5ODJOazJDQXEwT1Q5YUZpTzRnODZQY2lQY2NXR0lrV1NvVlVvTTVNZXlNdUJnanhRSjV2dkJzaTZkLVkxYlo1NGhTYzBlQVR0Y2c5WkdEaldxSW85bm50VU16RVVfNEE?oc=5", "title": "Stryker Aktie kaufen oder verkaufen? Analyse & Prognose 2026", "content_text": "Stryker Aktie kaufen oder verkaufen? Analyse & Prognose 2026", "date_published": "2026-08-01T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:7608353887ebb7e66a2eaebd0adb5c6e22c431fdbbefbe56d6c054c3a9e371f1", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Haben die starken Ergebnisse im zweiten Quartal, die angehobene Prognose und die Erholung im Cyberbereich das Anlage-Narrativ von Stryker (SYK) gerade ver\u00e4ndert?", "content_text": "Haben die starken Ergebnisse im zweiten Quartal, die angehobene Prognose und die Erholung im Cyberbereich das Anlage-Narrativ von Stryker (SYK) gerade ver\u00e4ndert?", "date_published": "2026-08-01T07:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:b7a4628279d7878e6b94abcbc0595093b1160d64ff84e38de2ee880116ac9343", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFB5anpVQjd0N2JCQ3dpc0pEczdoTE9wWkc4NEVwY29wVDY5Szk3V0JCemVkUVVLdjZ4aUFwM1VFYlplM0toWGFpeldBYjNvNmRnUFg1a2ZXNzhWTDFl?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFB5anpVQjd0N2JCQ3dpc0pEczdoTE9wWkc4NEVwY29wVDY5Szk3V0JCemVkUVVLdjZ4aUFwM1VFYlplM0toWGFpeldBYjNvNmRnUFg1a2ZXNzhWTDFl?oc=5", "title": "MDT|Medtronic PLC|Kurs:87.160|\u00c4nderung %:+1.240", "content_text": "MDT|Medtronic PLC|Kurs:87.160|\u00c4nderung %:+1.240", "date_published": "2026-07-24T14:11:19+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:5b8f28875141f124c5e25e7a7bc097a863ca385bdc74453ef5ba2298a2f91622", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQNnFYQU83eXFOazRwVlRRa1QyOUJ5ZEQyTXJ5RDlQdHdxTVZXM01GOFNnc09ZNFRuZ0NyWU1TQzRIY1dvRlNEcUZuZTdOQ3cteWJZdERuRks2ajR2UWxzcXNWenhhU3dmTlQxOXRhV2IzRmZ2dG1QV2w1U3QyVHNENVFmY1FaN0VmWEVpdllsVWFMZ2lBeVlqeWNyalZZR3Q0Q2EtazdKWHk4akdaeTlTRDBlME1kRXA1NVlQLTJ1OWNCV05IM0JmNllfT2xEM2kyVmtkUC1iZHlpMEJfWmp1THJDbEJSNFBtOVIyUS1vbFdadlh4?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQNnFYQU83eXFOazRwVlRRa1QyOUJ5ZEQyTXJ5RDlQdHdxTVZXM01GOFNnc09ZNFRuZ0NyWU1TQzRIY1dvRlNEcUZuZTdOQ3cteWJZdERuRks2ajR2UWxzcXNWenhhU3dmTlQxOXRhV2IzRmZ2dG1QV2w1U3QyVHNENVFmY1FaN0VmWEVpdllsVWFMZ2lBeVlqeWNyalZZR3Q0Q2EtazdKWHk4akdaeTlTRDBlME1kRXA1NVlQLTJ1OWNCV05IM0JmNllfT2xEM2kyVmtkUC1iZHlpMEJfWmp1THJDbEJSNFBtOVIyUS1vbFdadlh4?oc=5", "title": "Earnings Call Transkript: Medtronic \u00fcbertrifft im vierten Quartal 2026 die Erwartungen bei Umsatz und Gewinn", "content_text": "Earnings Call Transkript: Medtronic \u00fcbertrifft im vierten Quartal 2026 die Erwartungen bei Umsatz und Gewinn", "date_published": "2026-06-03T07:00:00+00:00", "authors": [{"name": "Investing.com Deutsch"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:ebb339da01e82bd7122a3e1a306e6879f2c3cf6f610514876516e2ac7df2f426", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPbTJMUXRKbnN2YTZMeUFQeVpaNmdMYkNMXzg1RS1pZGNYMTlMRXBScVZpTDMyNExELTI1ZEtvNXNUR24zdUZwYS03QVRhYTQxNzh3SHF6M19fdUNwUk1yMEFWZGpSLTN1V0I5SmhNR2Jnd01ZOW9tU0JhOWpMaWZ3YkRTZTc4WmstZVJwSjZMRlhnRTd3d1VEajdBaGtWdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPbTJMUXRKbnN2YTZMeUFQeVpaNmdMYkNMXzg1RS1pZGNYMTlMRXBScVZpTDMyNExELTI1ZEtvNXNUR24zdUZwYS03QVRhYTQxNzh3SHF6M19fdUNwUk1yMEFWZGpSLTN1V0I5SmhNR2Jnd01ZOW9tU0JhOWpMaWZ3YkRTZTc4WmstZVJwSjZMRlhnRTd3d1VEajdBaGtWdw?oc=5", "title": "Stryker Stock Fell 6% After Q1 2026 Earnings. Was the Selloff Overdone?", "content_text": "Stryker Stock Fell 6% After Q1 2026 Earnings. Was the Selloff Overdone?", "date_published": "2026-05-04T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:ccdf70c7d475b7c05e324ac9e0e49817ee46b264aef8dd667e4660b339b4bbc1", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBQaTJfZnlTc09xRWxZZEduWExFUzBrNnBIdFlfVWZkLU5KRFF6SWZWVHVScjctYzk4QzFrOVZqNVFjYVQ2MjhEVVJfb3BIU2lrQnUxS29KR1JCa011X3ZVamZGRWlpbjQzbHVWbnBYbHlaM1VRRjg2NE41OHVxZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBQaTJfZnlTc09xRWxZZEduWExFUzBrNnBIdFlfVWZkLU5KRFF6SWZWVHVScjctYzk4QzFrOVZqNVFjYVQ2MjhEVVJfb3BIU2lrQnUxS29KR1JCa011X3ZVamZGRWlpbjQzbHVWbnBYbHlaM1VRRjg2NE41OHVxZw?oc=5", "title": "Medtronic plc: Finanzdaten Prognosen Sch\u00e4tzungen und Erwartungen | A14M2J | IE00BTN1Y115", "content_text": "Medtronic plc: Finanzdaten Prognosen Sch\u00e4tzungen und Erwartungen | A14M2J | IE00BTN1Y115", "date_published": "2024-07-27T14:27:00+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}, {"id": "source:62906998811881581999461a81c8149bf1e582732e78a8a1bb1915a09f1ea114", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOZjFTRTFmMHJnVDlpSjJIOVY1a0xaUk9JMzZSZjRWMEctLVh3SGpfS2xrbl9OSnF2SGo3bjdOeUkwdTB3TVRBWl9IdmtBVWpzQy12WTVPbGZEam9KV0lqeERKdURzZzJtOU1CeVdqTG1tVWN3STFqTm11NkNlMG00ZXYxWVBBUjJCNVc0T3lB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOZjFTRTFmMHJnVDlpSjJIOVY1a0xaUk9JMzZSZjRWMEctLVh3SGpfS2xrbl9OSnF2SGo3bjdOeUkwdTB3TVRBWl9IdmtBVWpzQy12WTVPbGZEam9KV0lqeERKdURzZzJtOU1CeVdqTG1tVWN3STFqTm11NkNlMG00ZXYxWVBBUjJCNVc0T3lB?oc=5", "title": "Medtronic plc: Konsensus der Analysten und Kursziel | A14M2J | IE00BTN1Y115", "content_text": "Medtronic plc: Konsensus der Analysten und Kursziel | A14M2J | IE00BTN1Y115", "date_published": "2020-08-18T17:26:39+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/45567d37-de17-4e05-9610-bbcc129cb538/"}]}}]}